Skip to main content
U.S. flag

An official website of the United States government

LBD: Biomarker development (Milestone 9.P)

In Progress

Timeline Start - End

2016 - 2027

Research Implementation Area


AD-Related Dementias Focus

Develop and refine biomarkers for diagnosis, prediction, and prognosis utilizing biofluids, tissues, and digital and electrophysiological methods.  

Success Criteria

  • At least one clinical trial ready validated LBD biomarker that uses biofluids, tissues, digital or electrophysiological approaches (or a combination of approaches) for LBD diagnosis, prediction, and/or prognosis. 

Summary of Key Accomplishments

Several recently-funded awards are currently evaluating the utility of various biomarkers for LBD, including studies that are testing skin biopsies for abnormal alpha-synuclein in individuals with LBD, which appears to be a very promising biomarker assay that is extremely sensitive and specific for alpha-synuclein-related disorders. In one study, researchers demonstrated that this assay can successfully differentiate individuals with dementia with Lewy bodies (DLB) from individuals with Parkinson's disease (PD) even though both disorders develop abnormal alpha-synuclein deposits in the brain. Another research team showed that higher blood levels of a particular protein known as neurofilament light chain predicted which individuals with PD would go on to develop PD with dementia (PDD). Both alpha-synuclein and neurofilament light chain biomarker assays are being performed in the large, longitudinal NAPS2 study to determine if they are associated with progression from REM sleep behavior disorder to LBD.

The key accomplishments summary is current as of July 2022.  

Accomplishments/Implementation Activities

Funding Initiatives

Research Programs and Resources

Relevant Recommendations

Related Milestones

Search all Research Categories

An official website of the National Institutes of Health